enGene (NASDAQ:ENGN) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

enGene (NASDAQ:ENGN) released its quarterly earnings data on Tuesday. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.05, Yahoo Finance reports.

enGene Price Performance

Shares of NASDAQ:ENGN opened at $6.50 on Wednesday. The company’s fifty day moving average is $7.63 and its two-hundred day moving average is $11.59. The company has a debt-to-equity ratio of 0.09, a current ratio of 42.80 and a quick ratio of 42.80. enGene has a 1-year low of $4.94 and a 1-year high of $43.00.

Analyst Ratings Changes

Separately, Oppenheimer initiated coverage on enGene in a research note on Wednesday, August 28th. They set an “outperform” rating and a $30.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, enGene currently has a consensus rating of “Buy” and a consensus price target of $33.67.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.